ClinicalTrials.gg
CompletedNCT05028127Updated Aug 31, 2021

A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects

A Phase 1 interventional study of Bimekizumab in Healthy Volunteers, sponsored by UCB Celltech. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-31.

Sponsored by UCB Celltech (part of UCB S.A.) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 5 years 5 months after the study started (first participant enrolled Mar 2016, registered Aug 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of the study to determine the relative bioavailability of bimekizumab in healthy subjects

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Bimekizumab
  • Phase 1
03

In context

Lead sponsor

UCB Celltech is the lead sponsor of 8 studies on the registry; none are open to participants now.

First submitted after UCB Celltech became part of UCB S.A..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female aged ≥18 years and ≤65 years at the Screening Visit
  • Female subjects of child bearing potential must have a negative serum pregnancy test at the Screening Visit, which is confirmed to be negative by urine testing prior to the first dose of the Medicinal Product (IMP). Female subjects of must agree to use a highly effective method of during the study and for a period of 20 weeks after their last dose of the IMP
  • Subject must be in good health (physically and mentally) as determined by the Investigator on the basis of medical history (any chronic and acute illness), physical examination, vital signs, 12-lead , and laboratory screening tests during the Screening Period
  • Subject has a body weight of 45 to 90 kg (inclusive) and (BMI) between 19 and 28 kg/m\^2 (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Female subject who is pregnant, or plans to become pregnant during the study, or lactating, or sexually active with who is not using a medically accepted method. Male subjects who are planning a partner pregnancy during the study
  • Subjects receiving any live (includes attenuated) vaccination within the 8 weeks prior to Baseline (eg, inactivated influenza and pneumococcal vaccines are allowed but nasal influenza vaccination is not permitted). are not allowed during the study or for 20 weeks after the last dose of study drug
  • Subject has received any drug or experimental procedure within 90 days or 5 half-lives, whichever is longer, prior to IMP administration
  • Subject has a known to any components of the IMP as stated in this protocol
  • Subject has a current or past history of gastrointestinal ulceration or other gastrointestinal disease
  • Subject has cardiovascular or cerebrovascular disease, including hypertension, angina, ischemic heart disease, , stroke, peripheral arterial disease sufficient to cause symptoms, and/or requires therapy to maintain stable status
  • Subject has an active infection (eg, sepsis, pneumonia, abscess) or has had a serious infection (resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks prior to IMP administration
  • Study participant has a history of a positive tuberculosis (TB) test or evidence of possible TB or latent TB infection at the Screening Visit
  • Subject has concurrent acute or chronic viral or C or (HIV) infection
  • Subject has 12-lead with changes considered to be at Screening Visit and Day -1
  • Subject has active neoplastic disease or history of neoplastic disease within 5 years of Screening Visit (except for basal or squamous cell carcinoma of the skin or carcinoma in situ that has been definitively treated with standard of care)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Bimekizumab dosage regimen 1

    Subjects participating in the study will be receiving assigned bimekizumab dosage regimen 1 during the Treatment Period.

    Drug: Bimekizumab

  • Experimental
    Bimekizumab dosage regimen 2

    Subjects participating in the study will be receiving assigned bimekizumab dosage regimen 2 during the Treatment Period.

    Drug: Bimekizumab

Interventions

  • Subjects will be receiving bimekizumab at pre-specified time-points.

    Also known as: UCB4940, BKZ

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events including injection site reactions and systemic injection reactions

    An Adverse Event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.

    Time frame: From Screening Period (Day -21) until end of Safety-Follow-Up Visit (up to Day 85)

  2. Relative Bioavailability (BA) of Bimekizumab

    Time frame: Pre-dose (Day 1) until end of Safety-Follow-Up Visit (up to Day 85)

07

Study locations

1 site
  • Harrow, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Due to the small sample size in this trial, Individual Patient Data cannot be adequately anonymized and there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Jun 2016, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2021
First posted
Aug 31, 2021
StartActual
Mar 4, 2016
Primary completionActual
Jun 17, 2016
CompletionActual
Jun 17, 2016
Last update
Aug 31, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05028127
Lead sponsor
UCB Celltech
Responsible party
Sponsor
First posted
Aug 31, 2021
Start date
Mar 4, 2016
Primary completion
Jun 17, 2016
Completion
Jun 17, 2016
Last update
Aug 31, 2021

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion